Paclitaxel in Breast Cancer

Area of Science:

• Oncology
• Pharmacology
• Clinical Investigation

Background:

• Paclitaxel is a key agent in breast cancer treatment due to its efficacy and lack of cross-resistance with anthracyclines.
• Intensive clinical research focuses on optimizing paclitaxel's dose, scheduling, and combination therapies worldwide.

Purpose of the Study:

• To review the current clinical evidence on paclitaxel's efficacy and tolerability in various breast cancer settings.
• To highlight ongoing investigations into optimizing paclitaxel's use in early and advanced-stage breast cancer.

Main Methods:

• Review of recent clinical evidence and phase II/III investigations of paclitaxel.
• Analysis of single-agent and combination chemotherapy regimens, including dose and schedule optimization.

Main Results:

• Optimal single-agent paclitaxel dose by 3-h infusion is 175 mg/m²; 3-h infusion is not inferior to 24-h or 96-h infusions.
• Weekly moderate-dose paclitaxel shows promise with high dose intensity and manageable toxicity.
• Response rates range from 30%-60% in first-line metastatic disease and 20%-40% in second-line therapy.
• Combination regimens with doxorubicin, carboplatin, and trastuzumab show promise.
• Adjuvant paclitaxel improves disease-free and overall survival.

Conclusions:

• Paclitaxel is a highly active agent in both early and advanced breast cancer.
• Further research is optimizing paclitaxel's role, including weekly schedules and novel combinations like monoclonal antibodies.
• Innovative trials aim to maximize paclitaxel's potential for improved survival and quality of life in breast cancer patients.